{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001149","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2021-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.180514+00:00","generated_at":"2026-06-29T03:22:31.085871+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance","bullets":["Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.","FY2021 guidance lowered: net sales $1.18-$1.20B (prev $1.24-$1.28B); EPS $5.80-$6.00 (prev $6.15-$6.50).","CEO cites COVID disruptions, lockdowns, postponed events, and delayed product launches as headwinds.","Board increases share repurchase authorization to $150M (includes $14M remaining)."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001149","json":"https://secwatch.observer/filing/0001157523-21-001149.json","markdown":"https://secwatch.observer/filing/0001157523-21-001149.md","text":"https://secwatch.observer/filing/0001157523-21-001149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/0001157523-21-001149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/a52493306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:22:31.085871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}